Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cures Bill Authorizes Inter-Center Institutes, But Will US FDA Create Them?

Executive Summary

The agency is still working to get an oncology center of excellence off the ground and has other large pending reorganizations to tackle before it may get to creating additional centers intended to break down device, drug and biologic silos.

Advertisement

Related Content

Gottlieb Touts Devices For Pain Control To Help Solve Opioid Crisis
Combo-Product Sponsors Gain Some Favored Changes In Final Post-Market Reporting Rule
Combo Product Review Pilot At US FDA Will Offer All Applications Intercenter Consults
Combo Product Sponsors Convince US FDA To Change Postmarket Reporting Rule
21st Century Cures: Device Provisions
21st Century Cures: Device Provisions
Finally … Rachel Sherman Takes Califf's Old FDA Job
ORA Device Director: Inspection 'Program Alignment' Scheme Not Ready Anytime Soon; Investigator Training, Retention Pose Challenge For FDA
Look Before Leaping To Reorganize FDA – Former Commissioner McClellan

Topics

Advertisement
UsernamePublicRestriction

Register

MT104161

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel